Venclexta
VENCLYXTO is some form of chronic lymphocytic leukemia (cancer of the white blood cells), as well as (SLL; a type of cancer that begins mainly in the lymph nodes). As a first-line treatment for AML acute myeloid leukemia (cancer of the white blood cells), this drug may be administered alone or in combination with obinutuzumab (Gazyva), rituximab (Rituxan), azacitidine (Vidaza), decitabine (Dacogen), or cytarabine in patients 75 years of age and older or in adults with medical conditions that prevent them from receiving other chemotherapy drugs. The class of medications known as B-cell lymphoma-2 (BCL-2) inhibitors include venetoclax. It functions by preventing a body protein from aiding cancer cells in surviving. This helps to kill cancerous cells.
Venclyxto's Operation
The active component of Venclyxto, venetoclax, interacts with the Bcl-2 protein. Leukemia cancer cells contain high levels of this protein, which helps the cells survive longer in the body and develop resistance to cancer treatments. Venetoclax stops Bcl-2 from doing its job, which prevents the illness from progressing while killing cancer cells.
The fact that Venclyxto can be used with or without radiation is by far its greatest benefit. White blood cell count is recovered as a result. Additionally, it enables the patient to receive leukemia treatment as well as different immunotherapy medications including rituximab and obinutuzumab. As a result, the immune system can combat cancer cells in the body more successfully. Furthermore, Venclyxto may be more successful in helping patients with cancer defeat their disease than rituximab or other immunotherapy medications in improving their response to treatment. Additionally, Venclyxto can be used in conjunction with other leukemia treatments. By doing this, patients are guaranteed to receive all appropriate treatment for their disease. Additionally, it is a very effective drug that is well tolerated.
How Do You Use Venclyxto Capsules?
Venclyxto is only available with a valid prescription and should only be started and treated by a doctor with experience in cancer treatments. It is available as tablets (10, 50, and 100 mg), which should be taken once daily with food.
Starting at 20 mg daily, the dose of Venclyxto Capsules for CLL is gradually increased to 400 mg daily over the course of five weeks. The dosage is then maintained at 400 mg per day for the duration of the treatment, which is dependent on the drug it is given. As long as the drug is effective when taken by itself, Venclyxto is given. A 100 mg starting dose for AML is increased over three days to 400 mg daily. It could be essential to reduce the dose or stop taking the drug completely if certain negative symptoms appear.
What are Venclyxto's Side Effects?
Anemia and a decrease in neutrophils were the two most frequent significant adverse effects. Pneumonia, sepsis (blood poisoning), urinary tract infection (infection of the structures that carry urine), neutropenia (low levels of neutrophils, a type of white blood cells) with or without fever, anemia, thrombocytopenia (low levels of blood platelets), hypokalaemia (low levels of potassium), decreased appetite, dizziness, headache, nausea, diarrhea, vomiting, and stomatitis (in the mouth) are the most frequent side effects (high blood levels of bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes)
Bleeding, sepsis, anemia, thrombocytopenia, hypokalaemia, pneumonia, and neutropenia with or without fever are the most frequent serious side effects.
